RDY News and Press, Dr. Reddy's Laboratories Ltd

2026-02-20 11:40:07 ET More on Bristol-Myers Squibb Company, Dr. Reddy's Bristol-Myers: I'm Buying Post Earnings Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff NIH director rep...

Following the submission in December 2025, USFDA has accepted Dr. Reddy’s 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar Abatacept, DRL_AB (IV for Infusion) BLA is based on a robust data package supporting similarity to Orencia® (abatacept) ...

S&T Bancorp Inc. (STBA) is expected to report $0.89 for Q4 2025 Esquire Financial Holdings Inc. (ESQ) is expected to report $1.55 for Q4 2025 Atlantic Union Bankshares Corporation (AUB) is expected to report $0.86 for Q4 2025 Capital One Financial Corporation (COF) is expected to ...

2026-01-21 23:38:58 ET More on Dr. Reddy's Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript Dr. Redd...

2026-01-21 16:26:01 ET Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call January 21, 2026 9:00 AM EST... Read the full article on Seeking Alpha For further details see: Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript

2026-01-21 10:56:39 ET More on Dr. Reddy's, Novo Nordisk A/S Novo: Back From The Dead Novo Nordisk: Valuation Alone Doesn't Justify Bullishness Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Trump admin negotia...

2026-01-20 11:21:13 ET More on Dr. Reddy's Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript Seeking Alpha’s Quant Rating on Dr. Reddy's Historical earnings data for ...

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent ...

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1 st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancie...

2025-11-24 12:10:15 ET More on pharmaceuticals XPH: Small-Cap Pharma Turns Higher, At Long Last PPH: The Big Pharma ETF President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio Short bets on S&P 500 Healthcare sector rises to 2.00% in...